Sanofi
Biotech

Sanofi won't seek approval for eczema drug from Kymab buyout

The French pharma acknowledged that amlitelimab “would not represent a meaningful improvement” to existing treatments.
James Waldron Jul 24, 2026 5:13am
Scribe Therapeutics office in Alameda California

Scribe records upsized $129M IPO to fund genetic med trials

Jul 24, 2026 4:00am
a lot of scissors

Amgen sheds around 40 staffers as struggles mount

Jul 24, 2026 4:45pm
x

Fierce Biotech Layoff Tracker 2026: Amgen, Clinuvel & more

Jul 24, 2026 4:00pm
Red flag on a beach with a storm coming

Study reveals genetic red flags for CAR-T therapy side effects

Jul 24, 2026 2:00pm
handshake deal shake hand arrows ok yes
Favicon Fierce Pharma

Merck prepares expanded access to monthly PrEP pill early

Jul 24, 2026 10:40am
More News

Biogen R&D vet gets in Formation—Chutes & Ladders

Jul 24, 2026 8:30am

Scancell heads to Nasdaq via reverse merger with Neuphoria

Jul 23, 2026 10:13am

Lilly triple-G drug hits 22% weight loss, cardio impact unclear

Jul 23, 2026 9:06am

Australia's Clinuvel to shed up to 20% of workforce in US move

Jul 23, 2026 5:47am